Two Sigma Investments LP Buys 21,009 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Two Sigma Investments LP grew its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 216.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,709 shares of the company's stock after purchasing an additional 21,009 shares during the quarter. Two Sigma Investments LP's holdings in Henry Schein were worth $2,125,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Invesco Ltd. increased its stake in Henry Schein by 0.4% in the 4th quarter. Invesco Ltd. now owns 4,963,409 shares of the company's stock valued at $343,468,000 after buying an additional 17,552 shares during the last quarter. FMR LLC increased its position in shares of Henry Schein by 6.6% during the fourth quarter. FMR LLC now owns 3,498,033 shares of the company's stock valued at $242,064,000 after acquiring an additional 217,143 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Henry Schein by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,169,033 shares of the company's stock valued at $218,762,000 after acquiring an additional 14,876 shares during the last quarter. Palestra Capital Management LLC bought a new stake in Henry Schein during the fourth quarter worth $182,988,000. Finally, Fiduciary Management Inc. WI boosted its position in Henry Schein by 7.2% in the fourth quarter. Fiduciary Management Inc. WI now owns 2,488,335 shares of the company's stock worth $172,193,000 after purchasing an additional 167,990 shares during the last quarter. Institutional investors own 96.62% of the company's stock.

Henry Schein Stock Performance

Henry Schein stock traded up $1.01 during mid-day trading on Tuesday, reaching $70.57. The company's stock had a trading volume of 2,191,309 shares, compared to its average volume of 1,677,505. The firm's fifty day moving average price is $67.65 and its two-hundred day moving average price is $71.70. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.49. The company has a market capitalization of $8.59 billion, a P/E ratio of 29.04, a PEG ratio of 2.13 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. The company had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm's quarterly revenue was down .1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.10 earnings per share. Sell-side analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Philip A. Laskawy sold 2,604 shares of the company's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. This represents a 9.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now owns 62,688 shares of the company's stock, valued at approximately $4,460,251.20. This trade represents a 6.05% decrease in their position. The disclosure for this sale can be found here. 1.08% of the stock is currently owned by company insiders.

Analyst Ratings Changes

HSIC has been the subject of several research analyst reports. UBS Group decreased their target price on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research report on Wednesday, February 26th. Barrington Research reduced their price target on shares of Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Wall Street Zen lowered shares of Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Wells Fargo & Company dropped their target price on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Piper Sandler decreased their price target on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $79.30.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.